1416446-44-0

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 24608-52-4 tert-butyl chloroformate 

Downstream Products

• 1415901-86-8 3-({2-[(4-{amino-[(E)-tert-butyloxycarbonylimino]methyl}-phenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-yl-amino)propionic acid 
• 1415901-75-5 C₃₈H₄₃N₉O₅ 
• 1419178-58-7 3-({2-[(4-{amino-[(E)-tert-butyloxycarbonylimino]methyl}phenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-yl-amino)propionic acid {2-methoxy-4-[(E)-2-methoxycarbonylvinyl]phenyl} ester 

Relevant academic research and scientific papers

Design, synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing methyl ferulate

A novel series of prodrugs containing dabigatran and methyl (E)-3-(4-hydroxy-2-methoxyphenyl)propenoate (methyl ferulate) were synthesized. All of them reveal the effect of thrombin-induced anti-platelet aggregation in vitro. In addition, in vivo experiment shows that one of the target compounds, X-2 (ED50 = 3.7 ± 1.0 μmol/kg) possesses a more potent activity for inhibiting venous thrombosis than that of dabigatran etexilate (ED50 = 7.8 ± 1.5 μmol/kg).

Synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing a cleavable moiety with anti-platelet activity

A novel series of prodrugs consisting of dabigatran and 2-hydroxymethyl-3,5,6-trimethylpyrazine (HTMP) were synthesized. The pharmacological results show that all of them possess the effect of anti-platelet aggregation induced by thrombin in vitro. Moreover, one of those compounds, Y-2 (ED50 = 2.1 ± 1.3 mg/kg) shows more potent activity for inhibiting thrombosis in vivo than that of dabigatran etexilate (ED50 = 4.4 ± 2.2 mg/kg).